Probi is a leading player in probiotic research and the development of effective, well-documented probiotics.

The company’s research areas are gastrointestinal health, immunology, the metabolic syndrome and stress and recovery. Probi’s customers are leading companies in the fields of functional food and dietary supplements.

In 2009, revenues totalled MSEK 66.2, of which the majority comprised royalty revenues. The Probi share is listed on the NASDAQ OMX Nordic Exchange Stockholm, Small Cap. Probi has about 4,500 shareholders.